Volume 13, Issue 5 (Sep-Oct 2019)                   mljgoums 2019, 13(5): 19-25 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kargar M, Jamali H, Sadeghi M. Investigating Association of Human-Specific Derived Alleles of CD33 and Other Genes with Lifespan of Iranians. mljgoums 2019; 13 (5) :19-25
URL: http://mlj.goums.ac.ir/article-1-1247-en.html
Investigating Association of Human-Specific Derived Alleles of CD33 and Other Genes with Lifespan of Iranians
Mehdi Kargar 1, Hoshang Jamali2 , Mehdi Sadeghi3
1- Young Researchers and Elite Club, Shiraz Branch, Islamic Azad University, Shiraz, Iran
2- Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran
3- Department of Biochemistry, Shiraz Branch, Islamic Azad University, Shiraz, Iran
Abstract:   (7204 Views)
ABSTRACT
             Background and Objectives: Aging is a multi-agent phenomenon due to prolonged inflammation and stress. CD33 or Siglec3 is a membrane receptor that acts against aging by inhibiting inflammatory reactions. The aim of this study was to evaluate a possible relationship between CD33 copy number and lifespan of an Iranian population.
             Methods: The study included 50 individuals with cancer or Alzheimer's disease as the case group and 50 members of a family over 70 years old as the control group. Blood samples were collected and transferred to the laboratory. CD33 copy number was calculated using the QX100 Droplet Digital PCR system. A number of CD33 single-nucleotide polymorphisms including rs3865444, rs273634 and rs3852865 were genotyped using specific primers and the PCR method.
             Results: The mean number of CD33 copies among the case group (7.78) was significantly lower (P<0.05) than control group (12.72). In the case group, the mean number of CD33 copies was 7.83 among men and 7.73 among women. In the control group, the mean number of CD33 copies was 12.73 among men and 12.71 among women.
             Conclusion: CD33rSiglecs counteract random molecular damage, which is the main driver of aging. Therefore, the CD33rSiglec gene number may be correlated with longevity. Our results indicate that there may be a link between reduced CD33rSiglec copy number and development of diseases.
             Keywords: Gene Copy Number, Siglec-3, CD33 Antigens, Cancer.
Keywords: Gene Copy Number, Siglec-3, CD33 Antigens, Cancer.
Full-Text [PDF 839 kb]   (843 Downloads)    
Research Article: Original Paper | Subject: Sport Physiology
Received: 2019/08/31 | Accepted: 2019/08/31 | Published: 2019/08/31 | ePublished: 2019/08/31
References
1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153(6): 1194-217. doi: 10.1016/j.cell.2013.05.039. [DOI:10.1016/j.cell.2013.05.039]
2. Schwarz F, Fong JJ, Varki A. Human-specific evolutionary changes in the biology of siglecs. Adv Exp Med Biol. 2015; 842: 1-16. doi: 10.1007/978-3-319-11280-0_1. [DOI:10.1007/978-3-319-11280-0_1]
3. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol. 2009; 215(1): 5-19. doi: 10.1016/j.expneurol.2008.09.003. [DOI:10.1016/j.expneurol.2008.09.003]
4. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008; 70(19): 1672-7. doi: 10.1212/01.wnl.0000311269.57716.63. [DOI:10.1212/01.wnl.0000311269.57716.63]
5. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010; 9(2): 132-9. [DOI:10.2174/187152710791012026]
6. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The Global Distribution of Clinical Episodes of Plasmodium Falciparum Malaria. Natu. 2005; 434(3): 214-217. [DOI:10.1038/nature03342]
7. Angata T, Margulies EH, Green ED, Varki A. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proceedings of the National Academy of Sciences of USA. 2004; 101(5): 13251-13256. [DOI:10.1073/pnas.0404833101]
8. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014; 14(10): 653-66. doi: 10.1038/nri3737. [DOI:10.1038/nri3737]
9. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annual Review of Immunology. 2012; 30(6): 357-392. [DOI:10.1146/annurev-immunol-020711-075018]
10. La¨ubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci U S A. 2014; 111(39): 14211-6. doi: 10.1073/pnas.1409580111. [DOI:10.1073/pnas.1409580111]
11. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7(4): 255-66. [DOI:10.1038/nri2056]
12. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain. 2013; 136(3): 2677-2696. [DOI:10.1093/brain/awt210]
13. Yuan Q, Chu C, Jia J. Association studies of 19 candidate SNPs with sporadic Alzheimer's disease in the North Chinese Han population. Neurol Sci. 2012; 33(1): 1021-1028. doi: 10.1007/s10072-011-0881-0. [DOI:10.1007/s10072-011-0881-0]
14. Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM. Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 74-86. [DOI:10.1186/alzrt237]
15. Meyer M, Kircher M, Gansauge MT, Li H, Racimo F, Mallick S, et al. A high-coverage genome sequence from an archaic Denisovan individual. Science. 2012; 338(6104): 222-226. [DOI:10.1126/science.1224344]
16. Prüfer K, Racimo F, Patterson N, Jay F, Sankararaman S, Sawyer S, et al. The complete genome sequence of a Neanderthal from the Altai Mountains. Nature. 2014; 505(7481): 43-49. [DOI:10.1038/nature12886]
17. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5): 436-441. [DOI:10.1038/ng.801]
18. Kirkwood TB. Comparative life spans of species: why do species have the life spans they do? Am J Clin Nutr. 1992; 55(6 Suppl):1191S-1195S. doi: 10.1093/ajcn/55.6.1191Sa. [DOI:10.1093/ajcn/55.6.1191Sa]
19. Kapahi P, Boulton ME, Kirkwood TB. Positive correlation between mammalian life span and cellular resistance to stress. Free Radic Biol Med. 1999; 26(5-6): 495-500. [DOI:10.1016/S0891-5849(98)00323-2]
20. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, et al. Clinical significance of cd33 non-synonymous single nucleotide polymorphisms (snps) in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013; 19(6): 1620-1627. [DOI:10.1158/1078-0432.CCR-12-3115]
21. Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet. 2014; 23(10): 2729-36. doi: 10.1093/hmg/ddt666. [DOI:10.1093/hmg/ddt666]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.